We also observed that methiothepin increased the cytotoxicity of the inhibitor of MEK kinase trametinib (Figure 7B), and of the combined treatment vemurafenib/trametinib, which is currently used on patients with BRAFV600E melanoma (Figure 7C). The gene discussed is MAP2K7; the disease is melanoma.